The predictive value of coexisting BRAFV600E and TERT promoter mutations on poor outcomes and high tumour aggressiveness in papillary thyroid carcinoma: A …
B Chen, Y Shi, Y Xu, J Zhang - Clinical endocrinology, 2021 - Wiley Online Library
BRAFV600E mutation is highly prevalent in patients with papillary thyroid carcinoma (PTC),
and TERT promoter (TERTp) mutation is strongly associated with cancer‐related mortality …
and TERT promoter (TERTp) mutation is strongly associated with cancer‐related mortality …
The predictive value of coexisting BRAFV600E and TERT promoter mutations on poor outcomes and high tumour aggressiveness in papillary thyroid carcinoma: A …
B Chen, Y Shi, Y Xu, J Zhang - Clinical endocrinology, 2021 - pubmed.ncbi.nlm.nih.gov
BRAFV600E mutation is highly prevalent in patients with papillary thyroid carcinoma (PTC),
and TERT promoter (TERTp) mutation is strongly associated with cancer-related mortality …
and TERT promoter (TERTp) mutation is strongly associated with cancer-related mortality …
The predictive value of coexisting BRAFV600E and TERT promoter mutations on poor outcomes and high tumour aggressiveness in papillary thyroid carcinoma: A …
B Chen, Y Shi, Y Xu, J Zhang - Clinical Endocrinology, 2020 - europepmc.org
BRAFV600E mutation is highly prevalent in patients with papillary thyroid carcinoma (PTC),
and TERT promoter (TERTp) mutation is strongly associated with cancer-related mortality …
and TERT promoter (TERTp) mutation is strongly associated with cancer-related mortality …
The predictive value of coexisting BRAFV600E and TERT promoter mutations on poor outcomes and high tumour aggressiveness in papillary thyroid carcinoma: A …
B Chen, Y Shi, Y Xu, J Zhang - Clinical Endocrinology, 2020 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> BRAFV600E mutation is highly prevalent in
patients with papillary thyroid carcinoma (PTC), and TERT promoter (TERTp) mutation is …
patients with papillary thyroid carcinoma (PTC), and TERT promoter (TERTp) mutation is …
The predictive value of coexisting BRAFV600E and TERT promoter mutations on poor outcomes and high tumour aggressiveness in papillary thyroid carcinoma: A …
B Chen, Y Shi, Y Xu, J Zhang - Clinical Endocrinology, 2021 - search.ebscohost.com
BRAFV600E mutation is highly prevalent in patients with papillary thyroid carcinoma (PTC),
and TERT promoter (TERTp) mutation is strongly associated with cancer‐related mortality …
and TERT promoter (TERTp) mutation is strongly associated with cancer‐related mortality …